In a recent opinion column in Forbes, Grace-Marie Turner, founder and president of the Galen Institute, a nonprofit public policy research organization, said biosimilar prescription pharmaceuticals can provide an avenue to keeping drug prices low.
After the Healthcare Leadership Council (HLC) hosted a Capitol Hill bringing addressing the need for innovation in the nation’s healthcare workforce, the concerns now remain on how the industry is supposed to modernize during a time of varying factors.
U.S. lawmakers are considering a legislative proposal that would reauthorize the Prescription Drug User Fee Act (PDUFA) and potentially drive innovation in the pharmaceutical industry and among regulators.
Over one year ago, the U.S. Department of Health and Human Services (HHS) released their National Pain Strategy initiatives to help equip providers with the proper tools to institute better treatments for pain-centered ailments.
For months, the proposed merger of insurance giants Anthem and Cigna was in the news headlines as several groups opposed such an action, citing that such a commanding control of the health insurance market would not benefit patients.